|
Douglas Lind, MD is Managing Partner at GBP Capital, a Greenwich, CT-based healthcare venture firm. Dr. Lind has more than 20 years of experience in a variety of life science related professions, ranging from the practice of clinical medicine to senior Wall Street equity research analyst and venture capitalist. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson and Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by Astra Zeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals). Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed his residency training in Internal Medicine. He is currently a member of the board of directors of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.
|
